https://tip.inventingindices.com/marketbrain-2026-09-24-earnings-payx-paychex-raises-peo-growth-outlook-after-advisory-mix-shift The Tip Desk en 2026-09-24 Paychex Raises PEO Growth Outlook After Advisory Mix Shift https://tip.inventingindices.com/marketbrain-2026-09-24-earnings-gis-general-mills-restores-organic-sales-after-a-third-quarter-d The Tip Desk en 2026-09-24 General Mills Restores Organic Sales After a Third-Quarter Drop https://tip.inventingindices.com/marketbrain-2026-09-24-earnings-ctas-cintas-raises-fiscal-2027-outlook-after-record-margin The Tip Desk en 2026-09-24 Cintas Raises Fiscal 2027 Outlook After Record Margin https://tip.inventingindices.com/marketbrain-2026-09-24-diverging-saas-and-technology-profitability-trajectories-theme-70 The Tip Desk en 2026-09-24 Sprinklr Profit Flips as Asana, Planet Labs Stay Loss-Making https://tip.inventingindices.com/marketbrain-2026-09-24-deals-tech-bio-techne-shareholders-approve-merck-kgaa-s-11-3-billion-ca The Tip Desk en 2026-09-24 Bio-Techne Shareholders Approve Merck KGaA's $11.3 Billion Cash Bid https://tip.inventingindices.com/marketbrain-2026-09-24-deals-sui-aermont-completes-1-03-billion-cash-purchase-of-park-holiday The Tip Desk en 2026-09-24 Aermont Completes $1.03 Billion Cash Purchase of Park Holidays https://tip.inventingindices.com/marketbrain-2026-09-24-deals-rcl-royal-caribbean-to-form-3-billion-sandals-joint-venture The Tip Desk en 2026-09-24 Royal Caribbean to Form $3 Billion Sandals Joint Venture https://tip.inventingindices.com/marketbrain-2026-09-24-deals-onds-ondas-to-buy-three-defense-firms-in-56-million-mixed-deal The Tip Desk en 2026-09-24 Ondas to Buy Three Defense Firms in $56 Million Mixed Deal https://tip.inventingindices.com/marketbrain-2026-09-24-deals-hvii-one-nuclear-energy-to-go-public-via-hennessy-vii-combination The Tip Desk en 2026-09-24 ONE Nuclear Energy to Go Public via Hennessy VII Combination https://tip.inventingindices.com/marketbrain-2026-09-24-deals-fmc-fmc-to-buy-tessenderlo-group-in-403-million-cash-deal The Tip Desk en 2026-09-24 FMC to Buy Tessenderlo Group in $403 Million Cash Deal https://tip.inventingindices.com/marketbrain-2026-09-24-deals-arx-accelerant-go-shop-ends-with-no-rival-bids The Tip Desk en 2026-09-24 Accelerant Go-Shop Ends With No Rival Bids https://tip.inventingindices.com/marketbrain-2026-09-24-deals-apog-apogee-enterprises-completes-groglass-acquisition The Tip Desk en 2026-09-24 Apogee Enterprises Completes GroGlass Acquisition https://tip.inventingindices.com/marketbrain-2026-09-23-earnings-wor-worthington-organic-growth-rebounds-after-a-slow-close The Tip Desk en 2026-09-23 Worthington Organic Growth Rebounds After a Slow Close https://tip.inventingindices.com/marketbrain-2026-09-23-earnings-tho-thor-withholds-fiscal-2027-guidance-after-profit-collapse The Tip Desk en 2026-09-23 Thor Withholds Fiscal 2027 Guidance After Profit Collapse https://tip.inventingindices.com/marketbrain-2026-09-23-earnings-kbh-kb-home-backlog-rises-after-four-year-stagnation The Tip Desk en 2026-09-23 KB Home Backlog Rises After Four-Year Stagnation https://tip.inventingindices.com/marketbrain-2026-09-23-earnings-azo-autozone-reverses-gross-margin-decline-on-tariff-refunds The Tip Desk en 2026-09-23 AutoZone Reverses Gross-Margin Decline on Tariff Refunds https://tip.inventingindices.com/marketbrain-2026-09-23-deals-talo-talos-energy-closes-420-million-gulf-of-america-asset-purcha The Tip Desk en 2026-09-23 Talos Energy Closes $420 Million Gulf of America Asset Purchase https://tip.inventingindices.com/marketbrain-2026-09-23-deals-prgs-progress-software-to-buy-domo-platform-in-400-million-cash-d The Tip Desk en 2026-09-23 Progress Software to Buy Domo Platform in $400 Million Cash Deal https://tip.inventingindices.com/marketbrain-2026-09-23-deals-lgnd-ligand-to-buy-santen-s-ryjunea-for-23-million The Tip Desk en 2026-09-23 Ligand to Buy Santen's Ryjunea for $23 Million https://tip.inventingindices.com/marketbrain-2026-09-23-deals-cgnx-cognex-to-buy-realsense-in-500-million-cash-deal The Tip Desk en 2026-09-23 Cognex to Buy RealSense in $500 Million Cash Deal https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-vk2735-overview The Tip Desk en 2026-09-23 Viking’s GLP-1/GIP agonist advances through Phase 3 development https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-upadacitinib-overview The Tip Desk en 2026-09-23 AbbVie’s Rinvoq offers oral treatment for a defined colitis population https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-ulcerative-colitis-comparison The Tip Desk en 2026-09-23 Abivax, Merck and Teva–Sanofi pursue the next wave of colitis therapies https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-tulisokibart-overview The Tip Desk en 2026-09-23 Merck’s tulisokibart meets a Phase 3 ulcerative-colitis endpoint https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-tirzepatide-overview The Tip Desk en 2026-09-23 Lilly’s Zepbound sets an approved benchmark for dual-agonist obesity drugs https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-semaglutide-overview The Tip Desk en 2026-09-23 Novo Nordisk’s Wegovy provides an established obesity benchmark https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-risankizumab-overview The Tip Desk en 2026-09-23 AbbVie’s Skyrizi extends its IL-23 role into ulcerative colitis https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-retatrutide-overview The Tip Desk en 2026-09-23 Lilly’s triple agonist retatrutide heads toward a planned US filing https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-petrelintide-overview The Tip Desk en 2026-09-23 Roche and Zealand advance petrelintide’s amylin approach to obesity https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-petrelintide-enicepatide-introduction The Tip Desk en 2026-09-23 Roche and Zealand plan a two-mechanism obesity combination trial https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-orforglipron-overview The Tip Desk en 2026-09-23 Lilly’s Foundayo brings oral GLP-1 treatment into the obesity market https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-obesity-comparison The Tip Desk en 2026-09-23 Lilly and Novo set the backdrop for a changing obesity pipeline https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-obefazimod-overview The Tip Desk en 2026-09-23 Abivax’s obefazimod nears a planned US filing after Phase 3 readouts https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-mirikizumab-overview The Tip Desk en 2026-09-23 Lilly’s Omvoh follows induction with maintenance in ulcerative colitis https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-maridebart-cafraglutide-overview The Tip Desk en 2026-09-23 Amgen tests monthly obesity treatment with MariTide in Phase 3 https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-etrasimod-overview The Tip Desk en 2026-09-23 Pfizer’s Velsipity brings an oral option to ulcerative colitis https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-enicepatide-overview The Tip Desk en 2026-09-23 Roche’s enicepatide adds diabetes results as Phase 3 trials recruit https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-duvakitug-overview The Tip Desk en 2026-09-23 Teva and Sanofi take duvakitug into Phase 3 for ulcerative colitis https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-danuglipron-overview The Tip Desk en 2026-09-23 Pfizer’s oral GLP-1 program ended with danuglipron’s discontinuation